Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019 EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initial re...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news
World water day 2019
World Water Day - Making every drop countBoehringer Ingelheim started a social project in Mexico City to preserve the aquifer and to ensure the water supply for dog shelters First rainwater collector and filter will save 180,000 liters of rainwater every yearPublic campaign also promotes sterilization and adoption of shelter dogs (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 20, 2019 Category: Research Source Type: news
FDA-and-EMA-regulatory-submission-nintedanib-in-SSc-ILD
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILDSystemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue diseasePulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 15, 2019 Category: Research Source Type: news
NEJM-IL-36-Phase-1-GPP-data
Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline Flagship Store on TmallBoehringer Ingelheim launches its flagship store on an e-commerce platform TmallThe store specialises on the company ’s full range of pet parasiticidesBoehringer Ingelheim recognises e-commerce as paramount for its growth in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 27, 2019 Category: Research Source Type: news
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics developmentProgramme could lead to new diagnostic solutions for African swine feverBoehringer Ingelheim demonstrates its focus on prevention and innovation yet again (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news
New Chief Medical Officer appointed
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 22, 2019 Category: Research Source Type: news
Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Blockchain technology has the potential to improve trust, transparency, patient safety and patient empowerment in clinical trials (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 12, 2019 Category: Research Source Type: news
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim reaffirms its leading position in hatchery vaccination with its vector vaccines at IPPE 2019Vaxxitek ® HVT + IBD continues to lead in hatchery vector vaccination worldwideNewxxitek ® HVT + ND is Boehringer Ingelheim’s latest vectored vaccine against Newcastle disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 11, 2019 Category: Research Source Type: news
CAROLINA-top-line
For non-US, non-UK audiences (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news
Boehringer Ingelheim leader in hatchery vaccination with vector vaccines
Boehringer Ingelheim reaffirms its leading position in hatchery vaccination with its vector vaccines at IPPE 2019Vaxxitek ® HVT + IBD continues to lead in hatchery vector vaccination worldwideNewxxitek ® HVT + ND is Boehringer Ingelheim’s latest vectored vaccine against Newcastle disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - February 4, 2019 Category: Research Source Type: news
Launch of first veterinary vaccines produced in China
Boehringer Ingelheim launches first veterinary vaccines produced in ChinaThe first local manufacturing plant, wholly-owned by a multinational animal health company, focuses on the China swine marketThe Taizhou plant will produce PRRS vaccines and supply them locallyThe company delivers on its long-term ‘in China, for China’ commitment while accelerating its localisation strategy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 24, 2019 Category: Research Source Type: news
Boehringer_ingelheim_partners_with_ampath_in_Kenya
Boehringer Ingelheim partners with AMPATH to scale up knowledge, skills and training for healthcare providers in KenyaPartnership with AMPATH aims to advance Boehringer Ingelheim ’s Healthcare Initiative In Reach Africa Collaboration partnership to build a holistic and sustainable health system in Kenya (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 23, 2019 Category: Research Source Type: news
A_Healthy_2019
A healthy 2019: Four paws for more relaxation and exerciseAn international study confirms that the emotional bonds between people and their pets enhance health and well-beingOver 90 percent of pet owners say their animals have a positive effect on their quality of lifePets also help people stick to their New Year ’s resolutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2019 Category: Research Source Type: news
Capacity_expansion_OASIS
Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacitiesExpansion of manufacturing capacities in OASIS facilityIncreasing demands for world-class manufacturing in Shanghai, ChinaFirst commercial product manufacturing in Shanghai expected in 2019 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 17, 2019 Category: Research Source Type: news
